gimli

NOVARTIND stock AI analysis

NOVARTIND Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

NOVARTIS INDIA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available NOVARTIND price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive NOVARTIND stock page

Price

₹2,046.80

1W return

-15.71%

1M return

+28.21%

3M return

+50.03%

6M return

n/a

1Y return

n/a

Market cap

₹5,053.71 cr

51.69

6.18

ROE

+12.20%

ROCE

+12.92%

RSI

60.22

Turnover

₹15.72 cr

Why it can matter in screens

Momentum: NOVARTIND is above 50DMA, below 200DMA; RSI is 60.22.
Returns: 1D -1.70%, 1W -15.71%, 1M +28.21%, 3M +50.03%, 1Y n/a.
Trend levels: 52W high ₹2,588.80, 52W low ₹1,272.10, off high -20.94%.
Liquidity: latest turnover is ₹15.72 cr; volume vs 20D is +0.32%.
Valuation/profitability: PE 51.69, PB 6.18, ROE +12.20%, ROCE +12.92%.
Growth: 3Y sales CAGR -1.35%, 3Y profit CAGR -3.40%.

Quick Answers

What is the latest NOVARTIND stock price?

The latest stored price for NOVARTIND is Rs 2,046.80 as of 2026-09-18.

Is NOVARTIND above its 50DMA and 200DMA?

NOVARTIND is above 50DMA, below 200DMA. The latest 50DMA is 1,673.45 and the latest 200DMA is n/a.

What are NOVARTIND PE, ROE and ROCE?

NOVARTIND has PE 51.69, ROE +12.20%, and ROCE +12.92% in Gimli's latest available snapshot.

How has NOVARTIND performed recently?

NOVARTIND has returned +28.21% over 1 month, +50.03% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-06-30	103.81 cr	43.65 cr	32.21 cr	13.05
2026-03-31	90.55 cr	30.63 cr	25.25 cr	10.23
2025-12-31	85.90 cr	31.11 cr	16.09 cr	6.52
2025-09-30	99.73 cr	33.28 cr	24.22 cr	9.81
2025-06-30	87.55 cr	37.85 cr	27.62 cr	11.19
2025-03-31	83.88 cr	34.54 cr	29.30 cr	11.87
2024-12-31	93.00 cr	36.18 cr	25.45 cr	nan
2024-09-30	87.10 cr	28.28 cr	20.41 cr	8.27

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	354.33 cr	132.87 cr	93.18 cr	37.74
2025-03-31	356.27 cr	133.38 cr	100.90 cr	40.87
2024-03-31	334.04 cr	126.94 cr	85.19 cr	34.50
2023-03-31	369.11 cr	123.19 cr	103.36 cr	41.86
2022-03-31	433.06 cr	10.66 cr	-3.72 cr	-1.51

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	978.27 cr	52.50 cr	3.21 cr	817.83 cr
2025-03-31	947.81 cr	52.07 cr	5.06 cr	784.96 cr
2024-03-31	924.93 cr	44.98 cr	6.97 cr	744.82 cr
2023-03-31	982.94 cr	19.42 cr	21.51 cr	775.66 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	46.73 cr	46.39 cr	n/a
2025-03-31	74.57 cr	74.57 cr	n/a
2024-03-31	113.40 cr	113.40 cr	n/a
2023-03-31	44.80 cr	44.49 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

No recent data available.

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze NOVARTIS INDIA with valuation, momentum and industry peers
Compare NOVARTIND with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.